Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21784423 | 0.86 | KDM1A (0.50) | KDM1ARIPK1TACR1RORC | |
| SCHEMBL21784353 | 0.86 | KDM1A (0.50) | KDM1ARIPK1TACR1RORC | |
| SCHEMBL19025342 | 0.86 | KDM1A (0.50) | KDM1ARIPK1TACR1RORC | |
| SCHEMBL21784350 | 0.86 | KDM1A (0.50) | KDM1ARIPK1TACR1RORC | |
| SCHEMBL28654372 | 0.77 | KDM1A (0.50) | KDM1ARIPK1MAOAMAOBTACR1 | |
| SCHEMBL19609126 | 0.77 | MEN1 (0.49) | TACR1RORC | |
| SCHEMBL19025421 | 0.76 | KDM1A (0.47) | KDM1AMAOASIGMAR1HRH3 | |
| SCHEMBL23856027 | 0.75 | KDM1A (0.43) | KDM1AMAOAMAOBSIGMAR1 | |
| SCHEMBL18817699 | 0.75 | KDM1A (0.43) | KDM1AMAOAMAOBSIGMAR1 | |
| SCHEMBL28255285 | 0.75 | KDM1A (0.43) | KDM1AMAOAMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-10968200-B2 | Salts of an LSD1 inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200071289-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071289-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | KDM1A, KDM1B, KDM2A | KDM1A 1/4885RIPK1 1898/4885EPHX2 2868/4885 |
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | KDM1A, KDM1B, KDM2A | KDM1A 1/4885RIPK1 1898/4885EPHX2 2868/4885 |
| US-10968200-B2 | Salts of an LSD1 inhibitor and processes for preparing the same | KDM1A, KDM1B, KDM2A | KDM1A 1/4885RIPK1 1898/4885EPHX2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.